tbuckley/cabot-search huggingface dataset:
Novartis is under investigation for allegedly bribing thousands of Greek doctors
Authors: Owen Dyer
Journal: BMJ (2017)

Greece’s financial police have raided the Athens headquarters of Novartis, and a team of agents from the US Federal Bureau of Investigation have flown in to study seized company records, as part of an expanding probe into claims that the drug company has bribed over 4000 Greek doctors to prescribe or support the reimbursement of its drugs.

US investigators have been probing Novartis’s foreign marketing practices for two years. Greece’s investigation, ordered by the country’s supreme court prosecutor, was announced by the government after intense media speculation following a public suicide attempt on New Year’s Day by a Greek Novartis executive.

The executive had requested a …
Clinical factors associated with subclinical spread of in situ melanoma
Authors: Thuzar M. Shin, Jeremy R. Etzkorn, Joseph F. Sobanko, David J. Margolis, Joel M. Gelfand, Emily Y. Chu, Rosalie Elenitsas, Waqas R. Shaikh, Christopher J. Miller
Journal: Journal of the American Academy of Dermatology (2017)
Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom’s Macroglobulinemia.
Authors: Aldo Roccaro, Xavier Leleu, Anne-Sophie Moreau, Antonio Sacco, Lian Xu, Evdoxia Hatjiharissi, Bryan Ciccarelli, Christopher Patterson, Sophia Adamia, Domenico Russo, Angelo Vacca, Franco Dammacco, Kenneth Anderson, Irene Ghobrial, Steven Treon
Journal: Blood (2007)
S3 The uk’s largest severe asthma multidisciplinary team meeting; experience from the first 18 months
Authors: D Ryan, R Niven, H Burhan, J Corless, S Diver, S Fowler, D Menzies, R O’Driscoll, S Scott, N Sehgal, A Vyas, D Allen, J Blakey, B Kane
Journal: Thorax (2016)

<h3>Background</h3> Severe asthma comprises 5% of all asthma, but over 50% of the asthma healthcare burden. With multi-disciplinary team (MDT) working there is potential to improve patient outcomes and reduce healthcare costs. In 2013 NHS England produced service specifications for severe asthma aiming to develop a limited number of high volume specialist centres. In the North West we have developed a networked approach to specialised severe asthma services; the first Operation Delivery Network for a chronic disease. Representatives from 11 NHS Trusts and a central hub undertake a monthly virtual MDT meeting, with physicians, nurses, physiotherapists, clinical psychologists, speech and language therapists, allergists, pathologists and radiologists represented. All patients being considered for specialised treatments undergo MDT discussion for consensus approval of treatment. <h3>Aim</h3> To summarise the experience and case-mix encountered during the first 18 months of operation of our regional virtual severe asthma MDT <h3>Methods</h3> We reviewed all cases discussed at the MDT between January 2015 and June 2016. Cases were submitted online via nhs.net accounts, and data entered into a central database managed by two MDT coordinators for MDT discussion. <h3>Results</h3> During this period 17 meetings were held, with 208 case-submissions representing 185 patients, mean (SD) 12 (7) discussions per meeting. Indications for case submission included proposals for use of omalizumab, bronchial thermoplasty (BT), and steroid-sparing therapies, and for the discussion of patients with complex clinical issues, often managed across multiple sites. Omalizumab was approved in 81% of cases submitted, and BT in 39%, with more of the latter requiring multiple discussions (30% versus 2%) The most common reasons for non-approval of omalizumab were insufficient steroid requirement, poor adherence, and lack of allergy to a perennial allergen. Thermoplasty was not approved or listed for re-discussion for a variety of reasons, including 10 (43%) that required further investigation. <h3>Conclusion</h3> We describe our early experience of a multi-site virtual severe asthma MDT meeting facilitating expert care across a wide geographical area. This ensures governance in the use of novel and expensive severe asthma therapies, strengthens regional collaborations and ultimately aims to provide better patient care.
P1.08-002 The Prognostic Significance of Pleural Lavage Cytology before and after Lung Resection
Authors: Yohei Yurugi, Yoshiteru Kidokoro, Takashi Ono, Yasuaki Kubouchi, Makoto Wakahara, Ken Miwa, Kunio Araki, Yuji Taniguchi, Hiroshige Nakamura
Journal: Journal of Thoracic Oncology (2017)
Rectus Femoris Cross-Sectional Area and Muscle Layer Thickness: Comparative Markers of Muscle Wasting and Weakness
Authors: Zudin A. Puthucheary, Angela S. McNelly, Jai Rawal, Bronwen Connolly, Paul S. Sidhu, Anthea Rowlerson, John Moxham, Stephen D. Harridge, Nicholas Hart, Hugh E. Montgomery
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Supported by the U.K. National Institute of Health Research (NIHR) (Z.A.P.), the Batchworth Charitable Trust, the Moulton Charitable Foundation, and the NIHR University College London Hospitals Biomedical Research Centre (UCLH BRC) (A.S.M.), the Research Councils UK (S.D.H.), the NIHR Clinical Research Facility and BRC at Guy’s and St. Thomas’ National Health Service (NHS) Foundation Trust (GSST) and King’s College London (N.H. and B.C.), and by University College London and UCLH BRC (H.E.M., Z.A.P., and A.S.M.). The NIHR doctorate fellowship (2010–2014) underpinned the core patient population study on which this follow-up was built, as did funding from the Batchworth Charitable Trust, Moulton Foundation, and European Society of intensive Care Medicine. Additional funding was received from the Whittington Hospital NHS Trust and the European Society of Intensive Care Medicine.



Author Contributions: Concept and design—Z.A.P., P.S.S., J.M., S.D.H., N.H., and H.E.M.; data collection—Z.A.P., A.S.M., J.R., B.C., and A.R.; analysis and interpretation—Z.A.P., A.S.M., B.C., P.S.S., A.R., J.M., S.D.H., N.H., and H.E.M.; manuscript drafting and revision—Z.A.P., A.S.M., B.C., P.S.S., A.R., J.M., S.D.H., N.H., and H.E.M.



Author disclosures are available with the text of this letter at www.atsjournals.org.
P1.06-035 Frequency and Clinical Relevance of EGFR-Mutations and EML4-ALK-Translocations in Octagenarians with NSCLC
Authors: Amanda Tufman, Simone Reu, Sandra Hasmann, Diego Kauffmann-Guerrero, Katrin Milger, Zulfiya Syunyaeva, Kathrin Kahnert, Rudolf Huber
Journal: Journal of Thoracic Oncology (2017)
A Novel Perspective on Stem Cell Homing – Emerging Interplay Between Bioactive Lipids As Potent Chemoattractants and Cationic Peptides As Underappreciated Modulators of Responsiveness to SDF-1 Gradients
Authors: Chihwa Kim, Wu Wan, Nicholas J. Greco, Magda Kucia, Janina Ratajczak, Mary J. Laughlin, Mariusz Z Ratajczak
Journal: Blood (2011)
P2.03b-028 Improved Overall Survival Following Implementation of NGS in Routine Diagnostics of Advanced Lung Cancer in Germany: Results of the NGM
Authors: Anna Kostenko, Sebastian Michels, Jana Fassunke, Lucia Nogova, Sabine Merkelbach-Bruse, Matthias Scheffler, Vanessa Brandes, Rieke Fischer, Andreas Scheel, Florian Kron, Merle Schueller, Frank Ueckeroth, Reinhard Buettner, Jürgen Wolf
Journal: Journal of Thoracic Oncology (2017)
Angiographically Documented Coronary Steal Phenomenon Evoked by the Intracoronary Infusion of Bradykinin
Authors: Hajime Horie, Tetsuya Matsumoto, Masayuki Takahashi, Yuko Nakazawa, Hiroshi Yokohama, Kazuo Minai, Masahiko Kinoshita
Journal: Circulation (2001)

While studying flow-dependent coronary dilation using a Doppler flow velocity guidewire, total occlusion of a stenosed segment of the left circumflex artery during the intracoronary infusion of bradykinin was angiographically documented. Total occlusion was not demonstrated during intracoronary infusion of bradykinin after angioplasty. This is angiographic confirmation of the coronary steal phenomenon that has been previously described in the field of stress scintigraphy.
Outcomes of Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphocytic Leukemia (ALL) Post Blinatumomab Failure
Authors: Jenny Dahl, Hagop M. Kantarjian, Musa Yilmaz, Tapan Kadia, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur, Jorge E. Cortes, Alessandra Ferrajoli, Koji Sasaki, Jad Chahoud, Jane Autry, Rebecca Garris, Elias Jabbour
Journal: Blood (2015)
P1.02-018 Osteosarcomatous Differentiation in the Rebiopsy Specimens of Patients Harboring Pulmonary Adenocarcinoma with EGFR-TKI Resistance
Authors: Hyun Jung Kwon, Hyein Ahn, Eunhyang Park, Hyojin Kim, Jin-Haeng Chung
Journal: Journal of Thoracic Oncology (2017)
The Diminishing Role of Whole-Brain Radiation Therapy in the Treatment of Brain Metastases
Authors: Jing Li, Paul D. Brown
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Reply
Authors: Fabrice Lainé, Edouard Bardou‐Jacquet, Anita Paisant, Yves Gandon, Yves Deugnier
Journal: Hepatology (2017)

Potential conflict of interest: Nothing to report. Castiella et al. claim that liver iron concentration (LIC) is not increased in patients with hyperferritinemia and metabolic syndrome on the basis of a study1 in which LIC was measured using magnetic resonance imaging (MRI) in 54 patients referred for hyperferritinemia. However, this study has a major limitation, because 5% of patients had viral hepatitis and 35% were excessive drinkers (>40 g/day), two conditions that can induce hyperferritinemia without iron overload. Dysmetabolic iron overload syndrome (DIOS) is a well‐defined condition in which the usual causes of hyperferritinemia (e.g., alcohol, viral hepatitis, genetic hemochromatosis) have been excluded. Hyperferritinemia is associated with proven hepatic iron overload and one or more features of the metabolic syndrome. In the initial description of DIOS, the reality of hepatic iron excess was demonstrated by way of histology, determination of biochemical LIC, and calculation of iron removed.2 In our study,3 LIC was determined by way of MRI according to the widely used method of Gandon et al.4 The threshold of 50 µmol/g was chosen as an inclusion criterion because it was previously demonstrated to ensure hepatic iron excess with good specificity. Moreover, in our randomized study, the number of grams of iron subtracted by phlebotomy—the gold standard for the determination of body iron stores—was calculated in 126 patients. A mean of 12 ± 4 bimonthly phlebotomies, corresponding to 4.9 ± 1.6 L of blood removed (i.e., 2.45 ± 0.8 g of iron) were necessary to obtain low ferritin levels in these patients. This was in line with results of Jezequel et al.,5 who showed in a prospective matched‐controlled study that patients diagnosed as having DIOS on the basis of hyperferritinemia and LIC > 50 µmol/g at MRI had four times higher total body iron stores (2.5 ± 0.7 g) than overweight controls with normal serum ferritin (0.8 ± 0.3 g). In conclusion, our study included a large sample of strictly selected patients representative of DIOS. These patients had mild but unquestionable iron overload.
PUB140 A Pilot Study to Assess Circulating Tumor Cells, Circulating Tumor Cell DNA and Cell Free DNA in Patients with Small Cell Lung Cancer
Authors: Charu Aggarwal, Sunita Badola, Hyunjin Shin, Lisa Bedford, Sabrina Collins, Blair Derk, Jen Fostel, Jeffrey Ecsedy, Tracey Evans, Joshua Bauml, Roger Cohen, Anil Vachani, Corey Langer, Huifeng Niu
Journal: Journal of Thoracic Oncology (2017)
Government fails to assuage doctors’ concerns over NHS crisis
Authors: Zosia Kmietowicz, Gareth Iacobucci
Journal: BMJ (2017)

With its focus on targets rather than patient safety, and its underfunding of the NHS and social care, the government has failed to reassure doctors that it is dealing with the crisis in emergency care in England, medical leaders have said.

In response to the huge pressures being reported, England’s health secretary, Jeremy Hunt, effectively downgraded the four hour target for treating patients in hospital emergency departments by suggesting that the standard should exclude people with minor ailments.

In a statement in the House of Commons on Monday 9 January, Hunt said that the Tuesday after Christmas was the busiest day in the history of the NHS and that some hospitals were reporting that attendances in emergency departments were 30% higher than at the same time last year. He said it was time for “an honest discussion with the public about the purpose of A&E [accident and emergency] departments,” adding that no country outside the United Kingdom was committed to seeing all patients in emergency departments within four hours regardless of the seriousness of their ailments.

“Since [the target] was announced in 2000, there are nearly nine million more visits …
P3.03-062 Response to Pembrolizumab in a Malignant Pleural Mesothelioma with Sarcomatoid Histology: A Case Report
Authors: Martin Faehling, Birgit Schwenk, Sebastian Kramberg, Vera Wienhausen-Wilke, Matthias Leschke, Jörn Sträter
Journal: Journal of Thoracic Oncology (2017)
P2.01-084 Linker-Phosphorylated Smad2 and STAT3 Induce Resistance to Tyrosine Kinase Inhibition in Lung Cancer
Authors: Yojiro Makino, Eunjin Bae, Jeong-Hwan Yoon, Mizuko Mamura, Tatsuo Ohira, Masahiko Kuroda, Norihiko Ikeda
Journal: Journal of Thoracic Oncology (2017)
PL04a.04: Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC
Authors: Julien Adam, Isabelle Rouquette, Diane Damotte, Cécile Badoual, Claire Danel, Francesca Damiola, Frédérique Penault-Llorca, Sylvie Lantuejoul
Journal: Journal of Thoracic Oncology (2017)
Prognostic Models for Predicting Outcomes after Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin’s Disease: How Predictive Are They?.
Authors: Jose F. Leis, Keith S. Hansen, Peter T. Curtin, Brandon M. Hayes-Lattin, Keith S. Lanier, Nathan R. Stanton, Charles D. Callaway, Ceder J. Fowler, Adam M. Dunn, Daniel Gruenberg, Michael J. Mauro, Gerald M. Segal, Lisa K. Hansen, Jeffrey I. Menashe, Tibor J. Kovacsovics, Aleksandra Simic, Richard T. Maziarz
Journal: Blood (2005)
P2.04-025 Recombinant Human Endostatin and/or Cisplatin in Treatment of Malignant Hydrothorax and Ascites: A Multicenter Randomized Study
Authors: Shukui Qin, Ying Cheng, Qinghe Tan, Jingwang Bi, Liwei Wang, Bing Hu, Jianhua Shi, Guoping Sun, Yuxian Bai, Min Tao, Weijian Guo, Bing Lu, Jun Liang, Helong Zhang
Journal: Journal of Thoracic Oncology (2017)
Erratum to: “Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the diabetes prevention program” [Metabolism (2016) 65; 764–775]
Authors: Ronald B. Goldberg, Marinella Temprosa, Lisa Mele, Trevor Orchard, Kieren Mather, George Bray, Edward Horton, Abbas Kitabchi, Jonathan Krakoff, Santica Marcovina, Leigh Perreault, Neil White
Journal: Metabolism (2017)
OA09.03 Randomized Controlled Study Comparing Adjuvant versus Neo-Adjuvant Chemotherapy in Resectable Stage IB to IIIA NSCLC
Authors: Xue-Ning Yang, Wen-Zhao Zhong, Xiao-Song Ben, Hong-He Luo, Changli Wang, Qun Wang, Guibin Qiao, Hong-Hong Yan, Yi Long Wu
Journal: Journal of Thoracic Oncology (2017)
Clioquinol Arrests Cell Cycle at G1 Phase and Triggers Intrinsic Apoptosis In Myeloma and Leukemia Cells by Inhibiting Histone Deacetylases
Authors: Biyin Cao, Tingjun Hou, Suning Chen, Depei Wu, Aining Sun, Huiying Qiu, Wenjie Wang, Aaron Schimmer, Xinliang Mao
Journal: Blood (2010)
Long-Term Outcome of Immunosuppressive Therapy with Rabbit Antithymocyte Globulin (rATG) for Childhood Severe Aplastic Anemia for 15 Years
Authors: Dae-Chul Jeong, Nack Gyun Chung, Jae Wook Lee, Pil-sang Jang, Bin Cho, Hack-Ki Kim
Journal: Blood (2011)
S39 Risk of NTM (non tuberculous mycobacterium) infection in patients on long term prophylactic macrolide antibiotics
Authors: JB Adizie, M Qasim, M Pagaria
Journal: Thorax (2016)

<h3>Introduction</h3> Long term prophylactic macrolide therapy is commonly used in respiratory diseases characterised by persistent airway inflammation and chronic bacterial infection. There is growing evidence that they possess immuno-regulatory and anti-inflammatory effects as well as an antimicrobial action. The development of macrolide resistant bacteria, particularly NTM infection, is a concern because macrolide therapy is the primary treatment of NTM. There is little published data investigating this risk. <h3>Methods</h3> We identified the cases, retrospectively, of all adult patients who had been given long term continuous prophylactic macrolide therapy attending the respiratory outpatients clinic until January 2016 at Russell Hall Hospital. The clinic letters were reviewed to get a clinical diagnosis and then data regarding sputum culture results were collected from the electronic reporting system. Approximately 75% of cases were reviewed. <h3>Results</h3> 226 patient cases were reviewed. 192 (85%) were on long term Clarithromycin. 86 (38%) had a diagnosis of COPD; 133 (59%) of Non CF Bronchiectasis and 100 (44%) of Asthma. The average starting FEV1 was 1.55. The average change in FEV1 was −0.1 (range −3.22 to +1.07). Average time on macrolides was 3 years and 10 months (range 11 months to 8 years and 8 months). Out of all those who had sputum analysed, not one patient demonstrated evidence of NTM infection in their sputum up to 96 months (Figure 1). <h3>Conclusion</h3> Our data suggests that the use of long term prophylactic macrolide therapy in the treatment of respiratory disease does not increase the risk of NTM infection and therefore should not be a concern to limit use in clinical practice. However randomised controlled trials involving larger populations of patients are required to confirm the benefits and harms.
Nitric oxide mediates aortic disease in mice deficient in the metalloprotease Adamts1 and in a mouse model of Marfan syndrome
Authors: Jorge Oller, Nerea Méndez-Barbero, E Josue Ruiz, Silvia Villahoz, Marjolijn Renard, Lizet I Canelas, Ana M Briones, Rut Alberca, Noelia Lozano-Vidal, María A Hurlé, Dianna Milewicz, Arturo Evangelista, Mercedes Salaices, J Francisco Nistal, Luis Jesús Jiménez-Borreguero, Julie De Backer, Miguel R Campanero, Juan Miguel Redondo
Journal: Nature Medicine (2017)
P70 CPAP compliance in bariatric patients with obstructive sleep apnoea
Authors: PSP Cho, A Rainey, B Mukherjee, KK Lee
Journal: Thorax (2016)

<h3>Introduction</h3> CPAP compliance is a challenge in the management of obstructive sleep apnoea (OSA). Pre-operative screening with a sleep questionnaire for OSA followed by sleep studies is common in bariatric services. The King’s bariatric service performs overnight pulse oximetry in all patients considered for surgery. Therefore, additional cases may be detected in patients with lower clinical suspicion. We hypothesised that CPAP compliance in bariatric patients with OSA confirmed by routine screening would be lower than that seen in patients referred to the sleep clinic for suspected OSA. <h3>Method</h3> Case records of all bariatric patients screened for OSA over a 16-month period were reviewed, and CPAP compliance data retrieved for those with confirmed OSA who commenced CPAP therapy. Retrospective case-control analysis was made against 50 randomly selected patients from the sleep clinic that commenced CPAP for confirmed OSA within the same study period. CPAP compliance at 4 weeks was compared between the two groups. <h3>Results</h3> 409 patients were screened through the bariatric pathway during the study period. 49 (12.0%) patients were diagnosed with OSA and were commenced on CPAP. Baseline characteristics of the bariatric and sleep clinic groups are shown in Table 1. There was no significant difference between gender, baseline overnight desaturation indices and baseline Epworth Sleepiness Scale scores between the two groups. 21 (42.9%) patients in the bariatric group used their CPAP for ≥75% of nights within the 28-day period compared with 25 (50.0%) patients in the sleep clinic group; p = 0.48. There was a trend to significance for proportion of patients who used CPAP for mean ≥4 hours per night (20 (40.9%)) patients in the bariatric group vs 29 (58.0%) patients in the sleep clinic group; p = 0.087). <h3>Conclusion</h3> Our study suggests that the number of patients who are compliant with CPAP at mean use of ≥4 hours per night may be lower in those with confirmed OSA found on routine screening within a bariatric pathway than in patients referred to a sleep clinic, but our finding was limited by the small sample size. Future study to investigate this trend and its underlying causes could improve the success of intervention in the bariatric patients.
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Authors: Dan T. Vogl, Noopur Raje, Sundar Jagannath, Paul Richardson, Parameswaran Hari, Robert Orlowski, Jeffrey G. Supko, David Tamang, Min Yang, Simon S. Jones, Catherine Wheeler, Robert J. Markelewicz, Sagar Lonial
Journal: Clinical Cancer Research (2017)

Purpose: Histone deacetylase (HDAC) inhibition improves the efficacy of proteasome inhibition for multiple myeloma but adds substantial toxicity. Preclinical models suggest that the observed synergy is due to the role of HDAC6 in mediating resistance to proteasome inhibition via the aggresome/autophagy pathway of protein degradation.Experimental Design: We conducted a phase I/II trial of the HDAC6-selective inhibitor ricolinostat to define the safety, preliminary efficacy, and recommended phase II dose in combination with standard proteasome inhibitor therapy. Patients with relapsed or refractory multiple myeloma received oral ricolinostat on days 1-5 and 8-12 of each 21-day cycle.Results: Single-agent ricolinostat therapy resulted in neither significant toxicity nor clinical responses. Combination therapy with bortezomib and dexamethasone was well-tolerated during dose escalation but led to dose-limiting diarrhea in an expansion cohort at a ricolinostat dose of 160 mg twice daily. Combination therapy at a ricolinostat dose of 160 mg daily in a second expansion cohort was well tolerated, with less severe hematologic, gastrointestinal, and constitutional toxicities compared with published data on nonselective HDAC inhibitors. The overall response rate in combination with daily ricolinostat at ≥160 mg was 37%. The response rate to combination therapy among bortezomib-refractory patients was 14%. Samples taken during therapy showed dose-dependent increases of acetylated tubulin in peripheral blood lymphocytes.Conclusions: At the recommended phase II dose of ricolinostat of 160 mg daily, the combination with bortezomib and dexamethasone is safe, well-tolerated, and active, suggesting that selective inhibition of HDAC6 is a promising approach to multiple myeloma therapy. Clin Cancer Res; 23(13); 3307-15. ©2017 AACR.
Polymorphism 10034C&gt;T Is Located in a Functional Cleavage Stimulation Factor (CstF) Binding Site of the Fibrinogen Gamma Gene and Influences the γ′/γA mRNA Ratio.
Authors: Shirley Uitte de Willige, Inge M. Rietveld, Marieke C.H. de Visser, Hans L. Vos, Rogier M. Bertina
Journal: Blood (2006)